BioMerieux/ FR0013280286 /
8/29/2024 11:34:25 AM | Chg. - | Volume | Bid7/19/2024 | Ask7/19/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
105.60EUR | - | 54 Turnover: 5,702.40 |
-Bid Size: - | -Ask Size: - | 12.39 bill.EUR | 0.81% | 34.55 |
GlobeNewswire
6/3
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in P...
GlobeNewswire
4/18
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...
GlobeNewswire
12/4/2023
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire
9/20/2023
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire
10/4/2021
Quotient Limited Announces Appointment of New Chief Scientific & Medical Officer
GlobeNewswire
9/16/2021
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
GlobeNewswire
6/1/2021
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Upd...
GlobeNewswire
3/10/2021
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
GlobeNewswire
1/4/2021
Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass.
GlobeNewswire
9/17/2020
Victory Square Provides Corporate Update on the Strong Performance of Portfolio Companies